5:59 PM
 | 
Jan 14, 2013
 |  BC Extra  |  Company News

FDA approves Santarus' Uceris for ulcerative colitis

Santarus Inc. (NASDAQ:SNTS) said FDA approved Uceris budesonide to induce remission of mild to moderate active ulcerative colitis (UC). The company, which has...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >